Home Cart Sign in  
Chemical Structure| 314045-39-1 Chemical Structure| 314045-39-1

Structure of BPTES
CAS No.: 314045-39-1

Chemical Structure| 314045-39-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BPTES demonstrates potent inhibition of glutaminase through allosteric modulation, exhibiting selectivity with an IC50 of 0.16 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BPTES

CAS No. :314045-39-1
Formula : C24H24N6O2S3
M.W : 524.68
SMILES Code : O=C(NC1=NN=C(CCSCCC2=NN=C(NC(CC3=CC=CC=C3)=O)S2)S1)CC4=CC=CC=C4
MDL No. :MFCD01079848
InChI Key :MDJIPXYRSZHCFS-UHFFFAOYSA-N
Pubchem ID :3372016

Safety of BPTES

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • glutaminase

    Glutaminase GLS1 (KGA), IC50:0.16 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
K562 cells 5 μM or 10 μM 48 hours To evaluate the effect of BPTES on the survival and apoptosis of CD34+ cells from CML patients, results showed that BPTES significantly inhibited cell survival and induced apoptosis. PMC9486186
MDA-MB-231 10 µM 17 hours BPTES inhibits glutaminase activity, preventing the conversion of glutamine to glutamate and aμMonia, thereby reducing aμMonia accumulation and autophagy induction. PMC4502726
C2C12 10 µM 17 hours BPTES inhibits glutaminase activity, preventing the conversion of glutamine to glutamate and aμMonia, thereby reducing aμMonia accumulation and autophagy induction. PMC4502726
P493 cells 10 μM BPTES inhibited the growth of P493 lymphoma cells by causing DNA replication defects, leading to cell death and fragmentation. PMC4497742
mHCC 3–4 cells 10 μM BPTES inhibited the growth of mHCC 3–4 cells. PMC4497742
HIV-1-infected macrophages 10 μM 1 day To investigate the effect of BPTES on EV release in HIV-1-infected macrophages. Results showed that BPTES significantly decreased the levels of EV markers Alix, Flotillin-2, and tTG. PMC5853116
IμMune-activated BV2 microglia 10 μM 4 hours To investigate the effect of BPTES on EV release in iμMune-activated BV2 microglia. Results showed that BPTES significantly decreased the levels of EV markers Alix and Flotillin-2 in LPS-activated BV2 cells. PMC5853116
BMDMs 10 µM 1 hr Inhibition of glutaminase, reducing TNFα and IL-6 secretion PMC9555863
NSCLC cell lines 10 μM 48 hours BPTES treatment significantly reduced ATP levels and induced cell cycle arrest. PMC5261012
8305C cells 8 μM 48 hours To evaluate the effect of BPTES on cell proliferation, results showed that STAG2 knockdown cells exhibited significant growth inhibition when treated with BPTES PMC10361981
8505C cells 8 μM 48 hours To evaluate the effect of BPTES on cell proliferation, results showed that STAG2 knockdown cells exhibited significant growth inhibition when treated with BPTES PMC10361981
BCPAP cells 8 μM 48 hours To evaluate the effect of BPTES on cell proliferation, results showed that STAG2 knockdown cells exhibited significant growth inhibition when treated with BPTES PMC10361981
dNK cells 10 μM 48 hours BPTES significantly decreased the expression of Ki67 and cell size in dNK cells, promoted apoptosis of NK92 cells, and significantly impaired the invasion-promoting effect of dNK cells on HTR-8/SVneo cells. PMC11803016

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PDAC xenograft model Intraperitoneal injection 10 mg/kg Twice daily for 14 days To study the effect of BPTES on PI3K-C2γ-deficient PDAC xenograft models, results showed that BPTES significantly inhibited the growth of KO tumors. PMC9872233
Mice BCR-ABL(T315I)-induced CML model Intraperitoneal injection 125 mg/kg Enzastaurin, 12 mg/kg Ibrutinib Twice daily Enzastaurin, once daily Ibrutinib, for 21 days To evaluate the effect of BPTES in combination with PMF on LSCs in CML mice, results showed that the combination therapy significantly prolonged the survival of mice and markedly reduced LSCs. PMC9486186
Mice P493 tumor xenograft model Intraperitoneal injection 12.5 mg/kg Twice a week, for 2.5 weeks BPTES significantly prolonged the survival of LAP/MYC mice without any apparent toxicities. PMC4497742
BALB/c nude mice NSCLC xenograft model Oral 10 mg/kg Three times a week for three weeks Combination therapy of BPTES and 5-FU significantly inhibited tumor growth. PMC5261012
BALB/c nude mice 8505C xenograft model intraperitoneal injection 12.5 mg/kg body weight Every 3 days for 10 days To evaluate the therapeutic effect of BPTES on STAG2 knockdown tumors, results showed that BPTES significantly inhibited the growth of STAG2 knockdown tumors PMC10361981
mice pregnant mouse model intraperitoneal injection 10 mg/kg every three days until the end of the experiment BPTES significantly increased the embryo absorption rate, decreased placental weight and fetal crown-rump length, and impaired trophoblast invasion depth in the uterus. PMC11803016

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.91mL

0.38mL

0.19mL

9.53mL

1.91mL

0.95mL

19.06mL

3.81mL

1.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Xiang Y, Stine ZE, et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Invest. 2015 Jun;125(6):2293-306.

[2]Seltzer MJ, Bennett BD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15;70(22):8981-7.

[3]Lee JS, Kang JH, et al. Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC. Cell Death Dis. 2016 Dec 8;7(12):e2511.

[4]Elgogary A, Xu Q, et al. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):E5328-36.

[5]Yeh TK, Kuo CC, et al. Design, Synthesis, and Evaluation of Thiazolidine-2,4-dione Derivatives as a Novel Class of Glutaminase Inhibitors. J Med Chem. 2017 Jul 13;60(13):5599-5612.

[6]Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, Delahanty G, Alt J, Rais R, Rojas C, Gao P, Xiang Y, Dang CV, Slusher BS, Tsukamoto T. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012 Dec 13;55(23):10551-63. doi: 10.1021/jm301191p. Epub 2012 Nov 30. PMID: 23151085; PMCID: PMC3539823.

[7]Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, Dang CV, Riggins GJ. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov 15;70(22):8981-7. doi: 10.1158/0008-5472.CAN-10-1666. Epub 2010 Nov 2. PMID: 21045145; PMCID: PMC3058858.

[8]Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, Tsukamoto T, Rojas CJ, Slusher BS, Zhang H, Zimmerman LJ, Liebler DC, Slebos RJ, Lorkiewicz PK, Higashi RM, Fan TW, Dang CV. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012 Jan 4;15(1):110-21. doi: 10.1016/j.cmet.2011.12.009. PMID: 22225880; PMCID: PMC3345194.

 

Historical Records

Categories